1 / 14

RATIONAL PHARMACOTHERAPY: DIFFERENCES AMONG EUROPEAN COUNTRIES

RATIONAL PHARMACOTHERAPY: DIFFERENCES AMONG EUROPEAN COUNTRIES. SILVIO GARATTINI Istituto di Ricerche Farmacologiche Mario Negri - Milan Italy. COPENHAGEN 6 NOVEMBER 2002. 19. ACTIVE PRINCIPLES COMMON TO THREE COUNTRIES ACTIVE PRINCIPLES COMMON TO TWO COUNTRIES

kaleb
Download Presentation

RATIONAL PHARMACOTHERAPY: DIFFERENCES AMONG EUROPEAN COUNTRIES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RATIONAL PHARMACOTHERAPY: DIFFERENCES AMONG EUROPEAN COUNTRIES SILVIO GARATTINI Istituto di Ricerche Farmacologiche Mario Negri - Milan Italy COPENHAGEN 6 NOVEMBER 2002

  2. 19 ACTIVE PRINCIPLES COMMON TO THREE COUNTRIES ACTIVE PRINCIPLES COMMON TO TWO COUNTRIES ACTIVE PRINCIPLES PRESENT ONLY IN ONE COUNTRY 17 63

  3. ITALY UK GERMANY FRANCE CEFTRIAZONE MORNIFLUMATE ESAMEPRAZOLE FENOFIBRATE CLARITHROMYCIN GOSERELINE NADROPARINE PARACETAMOL LORAZEPAM LAMOTRIGINE CERTOPARINE ROXYTHROMYCIN ALPRAZOLAM GABAPENTINE ENOXAPARINE BUPRENORPHINE TAMSULOSINE SUMATRIPTAN FILGASTRIM GLICAZIDE BICALUTAMIDE MIRTAZAPINE DONEXEPIL TICLOPIDINE CERIVASTATIN NIMESULIDE 50 MOST SOLD DRUGS BY VALUE: DRUGS PRESENT IN ONLY ONE COUNTRY (2001)

  4. BELGIUM 10 GERMANY 10 ITALY 81 NETHERLANDS 8 PORTUGAL 9 SPAIN 16 UNITED KINGDOM 32 TOTAL 166 BASIC (BActeraemia Study in Intensive Care) Surveying antibiotic policy for bacteraemia in different countries

  5. Duration of antibiotic therapy in primary bacteremia PORTUGAL SPAIN BELGIUM ITALY GERMANY NETHERLAND UNITED KINGDOM 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% short (<6 days) medium (6-9 days) long (>9 days)

  6. Duration of antibiotic therapy in peritonitis related bacteremia PORTUGAL SPAIN BELGIUM ITALY GERMANY NETHERLAND UNITED KINGDOM 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% short (<6 days) medium (6-9 days) long (>9 days)

  7. Spectrum of antibiotic therapy in community acquired Gram + bacteremia PORTUGAL NETHERLAND SPAIN BELGIUM ITALY GERMANY UNITED KINGDOM 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% restricted broad

  8. INDUSTRIAL vs PUBLIC HEALTH INTEREST THE CASE OF EMEA WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

  9. SPC vs ADVERTISEMENT HOW TO PROMOTE INDIPENDENT INFORMATION? WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

  10. PASSIVE vs ACTIVE PHARMACOVIGILANCE THE NEED TO CENTRALIZE INFORMATIONS ON ADVERSE REACTIONS WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

  11. REVISION OF USELESS DRUGS ONLY FOR TOXICITY? WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

  12. MORE COMPARATIVE STUDIES AND LESS EQUIVALENCE STUDIES THE EUROPEAN LEGISLATION WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

  13. THE NEED OF INDIPENDENT STUDIES A PUBLIC EUROPEAN FUND FOR CLINICAL TRIALS WHY IS SO DIFFICULT TO IMPLEMENT RATIONAL PHARMACOTERAPY ?

More Related